Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 61 (12), 896-908

Citalopram Therapy for Depression: A Review of 10 Years of European Experience and Data From U.S. Clinical Trials

Affiliations
  • PMID: 11206593
Review

Citalopram Therapy for Depression: A Review of 10 Years of European Experience and Data From U.S. Clinical Trials

M B Keller. J Clin Psychiatry.

Abstract

Background: This review summarizes and evaluates clinical experience with citalopram, the latest selective serotonin reuptake inhibitor (SSRI) to be approved for the treatment of depression in the United States.

Data sources: Published reports of randomized, double-blind, controlled clinical studies of citalopram were retrieved using a MEDLINE literature search. Search terms included citalopram, SSRI, TCA (tricylic antidepressant), depression, and clinical. For each study, data on antidepressant efficacy and adverse events were evaluated. Pharmacokinetic studies and case reports were reviewed to supplement the evaluation of citalopram's safety and tolerability. Data presented at major medical conferences and published in abstract form also were reviewed.

Study findings: Thirty randomized, double-blind, controlled studies of the antidepressant efficacy of citalopram were located and reviewed. In 11 studies, citalopram was compared with placebo (1 of these studies also included comparison with another SSRI). In 4 additional studies, the efficacy of citalopram in preventing depression relapse or recurrence was investigated. In another 11 studies (including 1 meta-analysis of published and unpublished trials), citalopram was compared with tricyclic and tetracyclic antidepressants. Finally, results are available from 4 studies in which citalopram was compared with other SSRIs. A placebo-controlled study of citalopram for the treatment of panic disorder was reviewed for data on long-term adverse events.

Conclusion: Data published over the last decade suggest that citalopram is (1) superior to placebo in the treatment of depression, (2) has efficacy similar to that of the tricyclic and tetracyclic antidepressants and to other SSRIs, and (3) is safe and well tolerated in the therapeutic dose range of 20 to 60 mg/day. Distinct from some other agents in its class, citalopram exhibits linear pharmacokinetics and minimal drug interaction potential. These features make citalopram an attractive agent for the treatment of depression, especially among the elderly and patients with comorbid illness.

Similar articles

  • Citalopram in the Treatment of Depression
    NG Parker et al. Ann Pharmacother 34 (6), 761-71. PMID 10860138. - Review
    Clinical trials demonstrate that citalopram's therapeutic efficacy is significantly greater than that of placebo and is comparable with that of other antidepressants. Cit …
  • Citalopram--a Review of Pharmacological and Clinical Effects
    K Bezchlibnyk-Butler et al. J Psychiatry Neurosci 25 (3), 241-54. PMID 10863884. - Review
    There is evidence to support the role of citalopram as a well-tolerated and effective SSRI antidepressant. There is a need for further evaluation of its role in psychiatr …
  • A Systematic Review of Chinese Randomized Clinical Trials of SSRI Treatment of Depression
    Y Zhang et al. BMC Psychiatry 14, 245. PMID 25159460. - Review
    In light of the low trial quality, the findings of a significant advantage of SSRI over TCA in terms of response rate and remission rate should be replicated by large hig …
  • [Efficacy and Tolerability of Escitalopram in Anxiety Disorders: A Review]
    A Pelissolo. Encephale 34 (4), 400-8. PMID 18922243. - Review
    On the whole, numerous clinical data indicate that escitalopram, 10-20 mg/d, is an effective and well-tolerated first-line treatment option for the management of panic di …
  • The Antidepressant Efficacy of Citalopram
    SA Montgomery et al. Int Clin Psychopharmacol 11 Suppl 1, 29-33. PMID 8732442. - Review
    Depression is a long-term illness requiring psychopharmacological treatment over long periods of time. Treatments need to be effective and safe, but in an illness requiri …
See all similar articles

Cited by 20 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback